ATE195428T1 - Arznei für rheumatoide arthritis - Google Patents

Arznei für rheumatoide arthritis

Info

Publication number
ATE195428T1
ATE195428T1 AT95913319T AT95913319T ATE195428T1 AT E195428 T1 ATE195428 T1 AT E195428T1 AT 95913319 T AT95913319 T AT 95913319T AT 95913319 T AT95913319 T AT 95913319T AT E195428 T1 ATE195428 T1 AT E195428T1
Authority
AT
Austria
Prior art keywords
rheumatoid arthritis
medicine
remedy
monoclonal antibody
antibody recognizing
Prior art date
Application number
AT95913319T
Other languages
English (en)
Inventor
Tadashi Nishida
Sachiko Miyake
Hideo Yagita
Ko Okumura
Original Assignee
Kanebo Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kanebo Ltd filed Critical Kanebo Ltd
Application granted granted Critical
Publication of ATE195428T1 publication Critical patent/ATE195428T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT95913319T 1994-04-26 1995-03-22 Arznei für rheumatoide arthritis ATE195428T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP8825194 1994-04-26
PCT/JP1995/000527 WO1995028961A1 (en) 1994-04-26 1995-03-22 Remedy for rheumatoid arthritis

Publications (1)

Publication Number Publication Date
ATE195428T1 true ATE195428T1 (de) 2000-09-15

Family

ID=13937651

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95913319T ATE195428T1 (de) 1994-04-26 1995-03-22 Arznei für rheumatoide arthritis

Country Status (9)

Country Link
US (1) US5855888A (de)
EP (1) EP0759302B1 (de)
AT (1) ATE195428T1 (de)
DE (1) DE69518415T2 (de)
DK (1) DK0759302T3 (de)
ES (1) ES2151054T3 (de)
GR (1) GR3034200T3 (de)
PT (1) PT759302E (de)
WO (1) WO1995028961A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69934420T2 (de) * 1998-10-07 2007-09-27 Lennart Lindbom Anti-entzündliche alpha2, beta1 integrin-verwandte substanzen oder antikörper
ES2243259T3 (es) * 1999-04-22 2005-12-01 Biogen Idec Ma Inc. Metodo para tratar la fibrosis utilizando un antagonista de la subunidad alfa 4 de la integrina.
EP1181054A1 (de) 1999-06-01 2002-02-27 Biogen, Inc. Ein inhibierender monoklonaler antikörper gegen vla-1 und dessen verwendung zur behandlung von entzündungskrankheiten
US6146639A (en) * 1999-07-26 2000-11-14 Merich Nick Arthritis, muscle pain, and dry skin remedy
EP1423431B1 (de) * 2001-04-13 2010-06-16 Biogen Idec MA Inc. Antikörper gegen vla-1
US20030013107A1 (en) * 2001-06-07 2003-01-16 Rigel Pharmaceuticals, Incorporated Alpha 2 integrin: modulators of lymphocyte activation
PL1948798T3 (pl) 2005-11-18 2015-12-31 Glenmark Pharmaceuticals Sa Przeciwciała przeciwko integrynie alfa2 i ich zastosowania
CA2652815C (en) * 2006-05-25 2015-12-15 Biogen Idec Ma Inc. Methods of treating stroke
US20080267978A1 (en) * 2006-08-28 2008-10-30 Mary Zutter Anti-angiogenic targets for cancer therapy
ES2748577T3 (es) 2011-05-19 2020-03-17 Univ Michigan Regents Agentes de fijación de la integrina alfa-2 y uso de los mismos para inhibir la proliferación de las células de cáncer
WO2013123114A2 (en) 2012-02-16 2013-08-22 Santarus, Inc. Antibody formulations

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0330506A3 (de) * 1988-02-26 1990-06-20 Dana Farber Cancer Institute VLA-Proteine
DK162890D0 (da) * 1990-07-06 1990-07-06 Novo Nordisk As Polypeptid
NZ243706A (en) * 1991-07-25 1994-08-26 Idec Pharma Corp Recombinant monkey antibodies, pharmaceutical compositions

Also Published As

Publication number Publication date
DE69518415T2 (de) 2001-01-25
EP0759302B1 (de) 2000-08-16
GR3034200T3 (en) 2000-11-30
DE69518415D1 (de) 2000-09-21
EP0759302A4 (de) 1997-11-19
DK0759302T3 (da) 2000-11-13
EP0759302A1 (de) 1997-02-26
ES2151054T3 (es) 2000-12-16
PT759302E (pt) 2001-01-31
US5855888A (en) 1999-01-05
WO1995028961A1 (en) 1995-11-02

Similar Documents

Publication Publication Date Title
DE69518415D1 (de) Arznei für rheumatoide arthritis
ITMI921522A0 (it) Apparato di lavaggio e sterilizzazione di tappi di gomma, o simili impiegabili in confezioni farmaceutiche
DE69635582D1 (de) Diagnostika und behandlungen von peridontalen erkrankungen
FI973419A0 (fi) Epäorgaanisten aerogeelien käyttö lääkkeiden valmistuksessa
ATE236993T1 (de) Antithrombose mittel und gegen den von willebrand-faktor gerichtete monoklonale antikörper
FI893159A0 (fi) Laite ja menetelmä terveydenhuollossa syntyvien ongelmajätteiden käsittelemiseksi
FI961525A0 (fi) Uusi emulsioformulaatio
BR9406292A (pt) Complexo de inclusão de taxol ou taxotere ou extrato de taxus formados com ciclodextrinas sua preparação e uso
ATE433339T1 (de) Parasympathikomimetikum und parasympathikolytikum enthaltendes tts
DK0556322T3 (da) Aminosulfonylurinstof-ACAT-inhibitorer
FR2735132B1 (fr) Medicament polypeptidique modifie, composition et dispositif d'administration par electrotransport le contenant
ATE201828T1 (de) Verwendung eines cgrp antagonisten zur behandlung von flechten und pruritus und so erhaltene zubereitung
ES2133304T3 (es) Composiciones oftalmicas que comprenden combinaciones de un inhibidor de la anhidrasa carbonica y un antagonista beta-adrenergico.
DK0471718T3 (da) Paracetamolholdigt farmaceutisk præparat
ITRM910545A0 (it) Dispositivo trasportatore di bobine, rocche di filo e simili
ES2187618T3 (es) Utilizacion de compuestos de urea y de tiourea para la eliminacion o desintoxicacion de superantigenos de fluidos corporales.
ATE195055T1 (de) Insektizide zusammensetzung die diatomeenerde und siliziumdioxid enthalten
ATE107165T1 (de) Verwendung von macrolactonen als antiallergica.
DE69230644D1 (de) Verwendung von protease nexin-i als mittel gegen entzündungen
ATE122206T1 (de) Verminderung und inhibition des gehalts von äthylenthioharnstoff in alkylenbisdithiocarbamaten.
KR950701812A (ko) 렌티바이러스-유도된 질환의 치료에 유용한 생물학적으로 활성인 우레이도 유도체(Biologically active ureido dervatives useful in the treatment of lentivirus-induced sisease)
FR2690330B1 (fr) Dispositif destine a traiter certaines fractures siegeant entre massif trochanterien et 1/3 moyen de la diaphyse femorale.
ATE222255T1 (de) 14-substituierte marcfortine und derivate als antiparasitäre mittel
EA199600048A2 (ru) N,n-диэтил-8,8-дипропил-2-азаспиро[4,5]декан-2-пропанамин дималеат, фармацевтическая композиция на его основе и способ индуцирования иммуномодуляции
Matsumura et al. Detection of specific IgM antibodies to toxocaral ES antigen: effect of absorption of sera with protein A sepharose

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee